Summary

First-generation drug-eluting stents have reduced the risk of restenosis compared with bare-metal stents; however, these stents may have increased risk of stent thrombosis. Newer generation drug-eluting stents, which are constructed with biocompatible or biodegradable polymers, may have greater efficacy, safety, and device performance. The Randomized Clinical Comparison of Biomatrix Flex and Resolute Integrity trial [SORT-OUT VI; NCT01956448] compared the efficacy and safety of a zotarolimus-eluting stent with a biolimus-eluting stent in a population-based setting.